Novo Nordisk A/S
NYSE:NVODrug Manufacturers - General
-$0.48 today
- Market cap
- $173.82B
- Beta
- 0.35
- P/E (TTM)
- 10.2
- EPS (TTM)
- $27.45
- Dividend yield
- 4.18%
Volume 16.12M
Average 16.05M
NVO Account Payables
Amounts the company owes suppliers for goods and services received.
Novo Nordisk A/SNYSE: NVO
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables rises 448.8% from a year ago
Account payables stood at DKK 154.79B at the end of Q2 FY2026, up 448.8% from a year earlier and up 15.5% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Account payables amounted to 26.0% of total assets at the end of Q2 FY2026, up 20.2 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +448.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
DKK · from the balance sheet
- Latest · FY2025
- 19.76B DKK
- Year-over-year change
- -31.5%
- 4-year CAGR
- +22.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.76B | -31.5% |
| FY2024 | 2024-12-31 | 28.85B | +12.7% |
| FY2023 | 2023-12-31 | 25.61B | +64.3% |
| FY2022 | 2022-12-31 | 15.59B | +75.7% |
| FY2021 | 2021-12-31 | 8.87B | — |
Account Payables vs competitors
How NVO compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +448.8% is the 2nd highest of 10, against a peer median of -1.7%.
- Account payables amounts to 26.0% of total assets for NVO, versus a peer median of 18.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 154.79B DKK | +448.8% | +8.2% | 26.0% | |
| Jun 2026 | $33.17B USD | +4.2% | +7.0% | 24.5% | |
| Jun 2026 | €23.6B EUR | +233.5% | +2.6% | 18.3% | |
| Sep 2026 | $23.53B USD | -6.0% | +114.8% | 19.7% | |
| Jun 2026 | $20.06B USD | +566.3% | +14.6% | 21.0% | |
| Jun 2026 | £14.26B GBP | -29.8% | +58.4% | 23.2% | |
| Sep 2026 | $9.32B USD | -3.2% | +6.6% | 4.7% | |
| Jun 2026 | $6.11B USD | +50.0% | +40.7% | 4.3% | |
| Jun 2026 | $4.58B USD | -11.3% | -8.4% | 2.3% | |
| Jun 2026 | $3.83B USD | -1.7% | +1.1% | 2.9% | |
| Peer median (excluding NVO) | — | -1.7% | +7.0% | 18.3% | |
Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.72B | 12.65B | 14.39B | 15.66B | 26.46B |
| Short-term Investments | 6.77B | 10.92B | 15.84B | 10.65B | 498M |
| Net Receivables | 46.8B | 57.51B | 75.26B | 87.41B | 75.7B |
| Inventory | 19.62B | 24.39B | 31.81B | 40.85B | 49.62B |
| Other Current Assets | 1.69B | 9.67B | 2.34B | 6.33B | 20.17B |
| Total Current Assets | 85.6B | 108.19B | 139.65B | 160.9B | 172.45B |
| Property, Plant & Equipment (Net) | 55.36B | 66.67B | 90.96B | 162.49B | 208.38B |
| Goodwill | 4.35B | 5.09B | 4.46B | 20.06B | 19.85B |
| Intangible Assets | 38.83B | 46.32B | 55.94B | 91.03B | 110.21B |
| Long-term Investments | 1.44B | 1.34B | 1.66B | 2.68B | 2.51B |
| Tax Assets | 8.67B | 13.43B | 20.38B | 24.63B | 23.65B |
| Other Non-current Assets | 267M | 206M | 1.43B | 4.02B | 5.86B |
| Total Non-current Assets | 108.91B | 133.06B | 174.84B | 304.9B | 370.45B |
| Total Assets | 194.51B | 241.26B | 314.49B | 465.8B | 542.9B |
| Account Payables | 8.87B | 15.59B | 25.61B | 28.85B | 19.76B |
| Short-term Debt | 12.86B | 480M | 5.3B | 11.78B | 12.02B |
| Tax Payables | 3.66B | 7.09B | 7.12B | 9.72B | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 73.3B | 96.8B | 38.14B | 165.85B | 175.47B |
| Total Current Liabilities | 99.52B | 120.94B | 169.66B | 217.53B | 215.66B |
| Long-term Debt | 9.65B | 20.78B | 15.98B | 84.25B | 110.37B |
| Deferred Tax Liabilities | 5.27B | 7.06B | 10.16B | 5.43B | 6.61B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.01B | 5.45B | 7.58B | 9.68B | 7.64B |
| Total Non-current Liabilities | 24.25B | 36.83B | 38.27B | 104.78B | 133.19B |
| Total Liabilities | 123.76B | 157.77B | 207.93B | 322.31B | 348.86B |
| Common Stock | 462M | 456M | 451M | 446M | 446M |
| Retained Earnings | 72B | 80.59B | 104.84B | 144.45B | 195.3B |
| Accumulated OCI | (1.71B) | 2.45B | 1.28B | (1.41B) | (1.7B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 70.75B | 83.49B | 106.56B | 143.49B | 194.05B |
| Total Debt | 26.65B | 25.78B | 27.01B | 102.79B | 130.96B |
| Net Debt | 15.93B | 13.13B | 12.61B | 87.13B | 104.49B |
Novo Nordisk A/S
NYSE:NVO
Intrinsic Alpha fair value
Locked
Current Price
$39.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.